Recombinant Mouse CD300a/LMIR1 Fc Chimera Protein, CF
R&D Systems, part of Bio-Techne | Catalog # 1186-LM
Key Product Details
Source
NS0
Accession #
Structure / Form
Disulfide-linked homodimer
Conjugate
Unconjugated
Applications
Bioactivity
Product Specifications
Source
Mouse myeloma cell line, NS0-derived mouse CD300a/LMIR1 protein
| Mouse CD300a (Leu28-Arg183) Accession # BAC80268.1 |
IEGRMD | Human IgG1 (Pro100-Lys330) |
| N-terminus | C-terminus |
Purity
>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
Endotoxin Level
<0.10 EU per 1 μg of the protein by the LAL method.
N-terminal Sequence Analysis
Leu28
Predicted Molecular Mass
43.7 kDa (monomer)
SDS-PAGE
56-66 kDa, reducing conditions
Activity
Measured by its ability to inhibit anti-CD3-induced proliferation of stimulated human T cells.
The ED50 for this effect is 1-5 µg/mL.
Optimal dilutions should be determined by each laboratory for each application.
The ED50 for this effect is 1-5 µg/mL.
Optimal dilutions should be determined by each laboratory for each application.
Formulation, Preparation and Storage
1186-LM
| Formulation | Lyophilized from a 0.2 μm filtered solution in PBS. |
| Reconstitution |
Reconstitute at 100 μg/mL in PBS.
|
| Shipping | The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. |
| Stability & Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
|
Background: CD300a/LMIR1
cross‑linking of LMIR1 induces phosphorylation of tyrosine residues in the cytoplasmic domain. This leads to the recruitment of phosphatases SHIP, SHP-1, and SHP-2 and inhibition of NK cell, eosinophil, and mast cell activation (2, 3, 5-7). Cross‑linking of LMIR1 to other surface proteins such as SCF R or Fc epsilon RI on mast cells, Fc gamma RIIA on neutrophils, or CCR3 on mast cells and eosinophils inhibits downstream signaling from those receptors (4, 8‑10). LMIR1 cross‑linking also limits the in vivo activities of these cells with a subsequent reduction of allergic inflammation symptoms (4, 7, 9).
References
- Clark, G.J. et al. (2009) Trends Immunol. 30:209.
- Kumagai, H. et al. (2003) Biochem. Biophys. Res. Commun. 307:719.
- Yotsumoto, K. et al. (2003) J. Exp. Med. 198:223.
- Munitz, A. et al. (2006) J. Allergy Clin. Immunol. 118:1082.
- Cantoni, C. et al. (1999) Eur. J. Immunol. 29:3148.
- Munitz, A. et al. (2006) Blood 107:1996.
- Bachelet, I. et al. (2005) J. Immunol. 175:7989.
- Bachelet, I. et al. (2008) J. Immunol. 180:6064.
- Bachelet, I. et al. (2006) J. Allergy Clin. Immunol. 117:1314.
- Alvarez, Y. et al. (2008) Mol. Immunol. 45:253.
Alternate Names
CD300a, CLM8, CMRF-35H, IGSF12, IRC1, IRC2, IRp60, LMIR1, MAIR-I, Mcipr1, NKRL, Pigr4
Gene Symbol
CD300A
UniProt
Additional CD300a/LMIR1 Products
Product Documents for Recombinant Mouse CD300a/LMIR1 Fc Chimera Protein, CF
Product Specific Notices for Recombinant Mouse CD300a/LMIR1 Fc Chimera Protein, CF
For research use only
Loading...
Loading...
Loading...